Table 2. Double-blind randomized clinical trials.
| Study | Geschwind et al. (2013) 18 | Haïk et al. (2014) 23 | Otto et al. (2004) 25 | Varges et al. (2017) 24 |
|---|---|---|---|---|
| Design | Crossover | Crossover | Crossover | Crossover |
| Intervention (I) | Quinacrine | Doxycycline | Flupirtine | Doxycycline |
| Dosage | 300 mg/day | 100 mg/day | 300 mg/day | 100 mg/day |
| Median follow-up time (months) | 2 | 5.5 | 1.3 | 7 |
| Control (C) | Placebo | Placebo | Placebo | Placebo |
| Sampling (I:C) | 51 (23:28) | 121 (62:59) | 28 (13:15) | 13 (7:6) |
| Median age (±DP) | 63 (±9.4) | 63 (±10.1) | 59 (±9.9) | 65 (±10.0) |
| Gender (M–F) | 31–20 | 51–70 | 13–15 | 7–5 |
| Previous intervention | No | No | No | No |
| Primary outcome | Increased survival | Increased survival | Cognitive decline reduction* | Increased survival |
| Results | I = C | I = C | I > C | I = C |
| Measure of association | HR: 95% CI = 1.43 (0.58–3.53); p= 0.43 |
HR: 95% CI= 1.10 (0.8–1.7); p= 0.50 |
One-tailed t-test; p= 0.02 |
HR: 95% CI = 0.84 (0.24–2.97); p ≤ 0.50** |
Abbreviations: CI, confidence interval.
Notes: *Assessed by ADAS-Cog: cognitive subscale of the Alzheimer disease assessment scale (ADAS); ** the study did not specify the p-value associated with this HR on the double-blind randomized clinical trial group.